• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Regen BioPharma and NIH in Cancer Research Collaboration


20 January, 2016.

Regen BioPharma (San Diego, CA) has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to jointly explore the biology of the NR2F6 protein.

The collaboration will focus on identifying ligands for the nuclear receptor NR2F6, which has been identified as a potentially important immune cell inhibitor and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify agonists and antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system.

Related Videos